Immix Biopharma (IMMX) said Monday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation to NXC-201 as a potential treatment for relapsed/refractory AL amyloidosis.
The company said the designation is intended to accelerate the development and review of promising advanced regenerative medicines that target serious medical conditions.
Immix Biopharma said it is accelerating the enrollment for a phase 1b/2 trial of NXC-201 in AL amyloidosis, expecting to enroll 40 patients. The study's primary endpoints are complete response rate and overall response rate, with an update on the study scheduled for release in the first half of the year, the company added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。